Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + oxaliplatin + raltitrexed
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Bevacizumab + oxaliplatin + raltitrexed (also known as SALOX plus bevacizumab) is a combination therapy used in the treatment of metastatic colorectal cancer (mCRC). This regimen combines: - **Bevacizumab**: A recombinant humanized monoclonal antibody that inhibits angiogenesis by targeting vascular endothelial growth factor A (VEGF-A) - **Oxaliplatin**: A platinum-based chemotherapeutic agent - **Raltitrexed**: A thymidylate synthase inhibitor The combination has shown efficacy as a second-line treatment option for patients with metastatic colorectal cancer who have failed first-line fluorouracil-based chemotherapy regimens. In clinical studies, this combination demonstrated promising progression-free survival (PFS) and overall survival (OS) with a manageable safety profile.
- Other names
- raltitrexed plus oxaliplatin plus bevacizumabSALOX plus bevacizumab
02
Targets
Beyond the preview
Go deeper on bevacizumab + oxaliplatin + raltitrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + oxaliplatin + raltitrexed.